Intensity Therapeutics, Inc. is a biotechnology company whose mission is to greatly extend the lives of patients with cancer. Intensity Therapeutics is pioneering a new immune-based approach to treat cancer - in situ vaccination. The Company uses its DfuseRxSM platform technology to create new products capable of attenuating (killing) a tumor in a manner that allows for the adaptive immune system to recognize the cancer and attack tumors. Further information can be found at www.intensitytherapeutics.com
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/29/16 | $10,000,000 | Series A |
Batterson Venture Capital Declan Doogan M.D. FastForward Jim Mellon SalvaRx VCapital | undisclosed |
